Deutsche Bank upgrades Humana to Buy, nearly doubling price target to $441 on recovery hopes.

Deutsche Bank upgraded Humana from Hold to Buy, raising its price target from $235 to $441, signaling confidence in a recovery driven by stabilizing managed care and improving Medicare star ratings. Mizuho also raised its target to $335, citing a more favorable outlook on medical loss ratios. Humana's strong Q1 2026 results and rising Medicare Advantage membership support this positive outlook. However, risks remain, including upcoming star rating results and legal challenges, suggesting cautious optimism for investors.